DK1175489T3 - Oligonukleotider indeholdende en antisense-sekvens stabiliseret af en sekundær struktur og farmaceutiske præparater indeholdende disse oligonukleotider - Google Patents

Oligonukleotider indeholdende en antisense-sekvens stabiliseret af en sekundær struktur og farmaceutiske præparater indeholdende disse oligonukleotider

Info

Publication number
DK1175489T3
DK1175489T3 DK00910916T DK00910916T DK1175489T3 DK 1175489 T3 DK1175489 T3 DK 1175489T3 DK 00910916 T DK00910916 T DK 00910916T DK 00910916 T DK00910916 T DK 00910916T DK 1175489 T3 DK1175489 T3 DK 1175489T3
Authority
DK
Denmark
Prior art keywords
oligonucleotides
secondary structure
antisense sequence
oligonucleotide
pharmaceutical preparations
Prior art date
Application number
DK00910916T
Other languages
English (en)
Inventor
Claude Malvy
Andrei Maksimenko
Valerie Helin
Marina Gottikh
Original Assignee
Bioalliance Pharma Sa
Centre Nat Rech Scient
Inst Gustave Roussy Igr
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bioalliance Pharma Sa, Centre Nat Rech Scient, Inst Gustave Roussy Igr filed Critical Bioalliance Pharma Sa
Application granted granted Critical
Publication of DK1175489T3 publication Critical patent/DK1175489T3/da

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C12N15/1131—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against viruses
    • C12N15/1132—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against viruses against retroviridae, e.g. HIV
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/31—Chemical structure of the backbone
    • C12N2310/315—Phosphorothioates
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/32—Chemical structure of the sugar
    • C12N2310/322—2'-R Modification
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/34—Spatial arrangement of the modifications
    • C12N2310/345—Spatial arrangement of the modifications having at least two different backbone modifications
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/50—Physical structure
    • C12N2310/53—Physical structure partially self-complementary or closed

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Biomedical Technology (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Molecular Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • General Health & Medical Sciences (AREA)
  • Virology (AREA)
  • Microbiology (AREA)
  • Plant Pathology (AREA)
  • Biophysics (AREA)
  • Physics & Mathematics (AREA)
  • Biochemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • AIDS & HIV (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
DK00910916T 1999-03-09 2000-03-09 Oligonukleotider indeholdende en antisense-sekvens stabiliseret af en sekundær struktur og farmaceutiske præparater indeholdende disse oligonukleotider DK1175489T3 (da)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
FR9902921A FR2790757B1 (fr) 1999-03-09 1999-03-09 Oligonucleotides contenant une sequence antisens stabilises par une structure secondaire et compositions pharmaceutiques les contenant.

Publications (1)

Publication Number Publication Date
DK1175489T3 true DK1175489T3 (da) 2006-10-02

Family

ID=9542992

Family Applications (1)

Application Number Title Priority Date Filing Date
DK00910916T DK1175489T3 (da) 1999-03-09 2000-03-09 Oligonukleotider indeholdende en antisense-sekvens stabiliseret af en sekundær struktur og farmaceutiske præparater indeholdende disse oligonukleotider

Country Status (12)

Country Link
US (1) US7022832B2 (da)
EP (1) EP1175489B1 (da)
JP (1) JP2004500018A (da)
AT (1) ATE328074T1 (da)
AU (1) AU3295700A (da)
CA (1) CA2363255A1 (da)
DE (1) DE60028367T2 (da)
DK (1) DK1175489T3 (da)
ES (1) ES2265916T3 (da)
FR (1) FR2790757B1 (da)
PT (1) PT1175489E (da)
WO (1) WO2000053745A1 (da)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BR0211111A (pt) 2001-07-12 2004-06-22 Univ Massachusetts Molécula de ácido nucleico isolada, vetor, célula hospedeira, transgene, precursor de rna engenheirado, animal transgênico não humano, e, método de induzir a interferência de ácido ribonucleico de um gene alvo em uma célula
JP2008526213A (ja) * 2004-12-30 2008-07-24 トッド エム． ハウザー， 自己保護オリゴヌクレオチドを使用する、遺伝子発現を調節するための組成物および方法
EP1934348B1 (en) * 2005-10-11 2018-05-02 Ben-Gurion University Of The Negev Research And Development Authority Compositions for silencing the expression of vdac1 and uses thereof
WO2008039937A2 (en) * 2006-09-27 2008-04-03 Novarx Blocking of gene expression in eukaryotic cells
US7645578B2 (en) * 2006-10-31 2010-01-12 Agilent Technologies, Inc. Cleavage of RNA at redundant sites
EP2078079B1 (en) * 2006-11-01 2011-05-04 The Medical Research and Infrastructure Fund of the Tel-Aviv Sourasky Medical Center Adipocyte-specific constructs and methods for inhibiting platelet-type 12 lipoxygenase expression
WO2010045384A2 (en) 2008-10-15 2010-04-22 Somagenics Inc. Short hairpin rnas for inhibition of gene expression
CN102264898B (zh) 2008-10-23 2013-10-16 国立大学法人东京大学 微小rna的功能抑制方法
US8871730B2 (en) 2009-07-13 2014-10-28 Somagenics Inc. Chemical modification of short small hairpin RNAs for inhibition of gene expression
SG186899A1 (en) 2010-07-08 2013-02-28 Bonac Corp Single-strand nucleic acid molecule for controlling gene expression
ES2533129T3 (es) 2010-08-03 2015-04-07 Bonac Corporation Molécula de ARN monocatenario que tiene esqueleto alicíclico que contiene nitrógeno
US9663784B2 (en) 2012-05-26 2017-05-30 Bonac Corporation Single-stranded nucleic acid molecule for regulating expression of gene having delivering function
WO2014144942A2 (en) * 2013-03-15 2014-09-18 Pronai Therapeutics, Inc. Dnai for the modulation of genes
WO2015099122A1 (ja) 2013-12-26 2015-07-02 学校法人東京医科大学 遺伝子発現制御のための人工ミミックｍｉＲＮＡおよびその用途
SG10201805087VA (en) 2013-12-27 2018-07-30 Bonac Corp Artificial match-type mirna for controlling gene expression and use therefor
WO2016104775A1 (ja) 2014-12-27 2016-06-30 株式会社ボナック 遺伝子発現制御のための天然型ｍｉＲＮＡおよびその用途
JP6602847B2 (ja) 2015-03-27 2019-11-06 株式会社ボナック デリバリー機能と遺伝子発現制御能を有する一本鎖核酸分子
IL267614A (en) 2019-06-24 2019-09-26 Lotem Michal Nucleic acids to modulate SLAMF6 isoforms
CN116262919A (zh) 2021-12-14 2023-06-16 成都凌泰氪生物技术有限公司 一种基于miRNA-2911的核酸分子
WO2025096807A2 (en) * 2023-10-31 2025-05-08 Flagship Pioneering Innovations Vii, Llc Novel therapeutic dna forms
US20260000702A1 (en) 2024-06-26 2026-01-01 Flagship Pioneering Innovations Vii, Llc Therapeutic circular dna forms

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1994001550A1 (en) * 1992-07-02 1994-01-20 Hybridon, Inc. Self-stabilized oligonucleotides as therapeutic agents
GB2273932A (en) * 1992-11-24 1994-07-06 Stiefel Laboratories Stable oligonucleotides
FR2703053B1 (fr) * 1993-03-26 1995-06-16 Genset Sa Oligonucleotides agrafes et semi-agrafes, procede de preparation et applications .
US5631148A (en) * 1994-04-22 1997-05-20 Chiron Corporation Ribozymes with product ejection by strand displacement

Also Published As

Publication number Publication date
EP1175489B1 (fr) 2006-05-31
PT1175489E (pt) 2006-10-31
WO2000053745A1 (fr) 2000-09-14
DE60028367D1 (de) 2006-07-06
US20020156261A1 (en) 2002-10-24
AU3295700A (en) 2000-09-28
JP2004500018A (ja) 2004-01-08
FR2790757A1 (fr) 2000-09-15
ATE328074T1 (de) 2006-06-15
US7022832B2 (en) 2006-04-04
WO2000053745A9 (fr) 2001-11-08
FR2790757B1 (fr) 2003-08-01
DE60028367T2 (de) 2007-02-08
CA2363255A1 (fr) 2000-09-14
ES2265916T3 (es) 2007-03-01
EP1175489A1 (fr) 2002-01-30

Similar Documents

Publication Publication Date Title
PT1175489E (pt) Oligonucleotidos contendo uma sequencia antisense estabilizada por uma estrutura secundaria e composicoes farmaceuticas contendo as mesmas
ES2243608T5 (es) Procedimiento y medicamento para la inhibición de la expresión de un gen predeterminado
DE69934227D1 (de) Auf beta-arabinose, und dessen analogen, basierte antisense oligonukleotide
BR0108959A (pt) Composições de polox‰mero ou poloxamina melhoradas para distribuição de ácido nucléico
ATE479752T1 (de) Therapeutische zusammensetzungen
MX2008014100A (es) Compuestos y metodos para modular la expresion de pcsk9.
HU9501963D0 (en) 7-deazapurine modified oligonucleotides
DE60329220D1 (de) Antisense-entwurf
EP1325019A4 (en) ANTISENSE MODULATION OF CLUSTERINEXPRESSION
WO2003020949A3 (en) Targeted nucleic acid constructs and uses related thereto
EP1417351A4 (en) ANTISENSE MODULATION OF THE EXPRESSION OF APOLIPOPROTEIN (A)
WO2001032832A3 (en) Antisense inhibition of nucleolin expression
PT1053313E (pt) Oligonucleotidos ''antisense'' optimizados complementares de sequencias de dna metiltransferase
EP1250157A4 (en) ANTISENS MODULATION OF THE EXPRESSION OF THE INDUCIBLE NITROGEN MONOXIDE SYNTHASE
WO2003101394A3 (en) Defensins: use as antiviral agents
EP1250347A4 (en) ANTISENSE MODULATION OF THE AKT-3 EXPRESSION
EP1163373A4 (en) ANTISENSE MODULATION OF THE CELLULAR INHIBITANT OF THE APOPTOSIS EXPRESSION
EP1248633A4 (en) ANTISENSE MODULATION OF THE EXPRESSION OF GLYCOGEN SYNTHASE KINASE 3 BETA
ITMI20030860A1 (it) Metodo per l'inibizione selettiva del gene n-myc
Yamakawa et al. Properties of nicked and circular dumbbell RNA/DNA chimeric oligonucleotides containing antisense phosphodiester oligodeoxynucleotides
EP1248635A4 (en) ANTISENSE MODULATION OF THE GLYCOGEN SYNTHASE-KINASE-3ALPHA EXPRESSION
WO2005039480A8 (en) AChE ANTISENSE DEOXYOLIGONUCLEOTIDE AS AN ANTI-INFLAMMATORY AGENT
Disney et al. Contributions of individual nucleotides to tertiary binding of substrate by a Pneumocystis carinii group I intron
Pascolo et al. Relative contribution of photo-addition, helper oligonucleotide and RNase H to the antisense effect of psoralen-oligonucleotide conjugates, on in vitro translation of Leishmania mRNAs
Hou et al. Inhibition of tRNA Aminoacylation by 2 ‘-O-Methyl Oligonucleotides